{"id":4727,"date":"2025-10-06T14:15:02","date_gmt":"2025-10-06T11:15:02","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=4727"},"modified":"2025-10-06T14:51:39","modified_gmt":"2025-10-06T11:51:39","slug":"zydus-lifesciences-receives-fda-approval-for-deflazacort-to-treat-dmd","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/de\/zydus-lifesciences-receives-fda-approval-for-deflazacort-to-treat-dmd\/","title":{"rendered":"Zydus Lifesciences erh\u00e4lt FDA-Zulassung f\u00fcr Deflazacort zur Behandlung von DMD"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Am Montag, den 6. Oktober, gab das Pharmaunternehmen Zydus Lifesciences bekannt, dass FDA die endg\u00fcltige Zulassung f\u00fcr seine orale Suspension von Deflazacort in einer Dosierung von 22,75 mg\/ml erteilt hat. Das Produkt enth\u00e4lt 22,75 mg\/ml Emflaza-Suspension zum Einnehmen in generischer Form.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Was ist Deflazacort (Emflaza)?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Patienten ab f\u00fcnf Jahren mit Duchenne-Muskeldystrophie (DMD) k\u00f6nnen mit Deflazacort-Suspension zum Einnehmen behandelt werden. Als Steroid hilft das Medikament, Entz\u00fcndungen zu reduzieren und ein \u00fcberreagierendes Immunsystem zu beruhigen.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Das Produkt wird laut Zydus im italienischen Doppel hergestellt. Mit dieser Zulassung erh\u00f6ht sich die Gesamtzahl der Zulassungen der Gruppe auf 424.<\/p>","protected":false},"excerpt":{"rendered":"<p>On Monday, October 6, pharmaceutical company Zydus Lifesciences announced that the FDA has given its final approval for its oral suspension of deflazacort at a dose of 22.75 mg\/mL. The product contains 22.75 mg\/mL of Emflaza oral suspension in a generic form. What is Deflazacort (Emflaza)? Patients five years of age and older with Duchenne [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4728,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[45],"tags":[211,428,88,429],"class_list":["post-4727","post","type-post","status-publish","format-standard","has-post-thumbnail","category-approved-therapies-for-duchenne-muscular-dystrophy","tag-deflazacort","tag-emflaza","tag-fda","tag-zydus-lifesciences"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/posts\/4727","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/comments?post=4727"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/posts\/4727\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/media\/4728"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/media?parent=4727"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/categories?post=4727"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/tags?post=4727"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}